THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in stromal rich tumours UK clinical trial ...

The investigational combination of avutometinib (a dual RAF/MEK inhibitor) and defactinib (a FAK inhibitor) achieved very high response rates in heavily pretreated patients with recurrent low-grade ...

Several factors make ovarian cancer particularly challenging to treat. This is largely because the cancer often spreads at a microscopic level within the abdomen early on, resulting in diagnosis at an ...

When Angelina Reardon went in for a routine scan in 2021, she never imagined her life was about to change forever. What ...

mRNA injections could reduce aggressive ovarian tumors by rescuing an often mutated gene in high-grade serous ovarian patients, according to a preclinical study. The most common form of ovarian cancer ...

The Phase 1 results and Cyclin E1 biomarker findings accepted for presentation at AACR-NCI-EORTC reinforce our biomarker-driven strategy for azenosertib in Cyclin E1-positive platinum-resistant ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced results of the first-ever LGSOC ...

In the field of gynecologic cancer, low-grade serous ovarian cancer (LGSOC) has been poorly understood and underinvestigated until recently. Similarly, understanding of the distinct properties and ...

One day, Emma Schlamm, then 25, felt an unusual pain in her left side. It didn’t feel like menstrual cramps, so she visited her doctor to learn more. A scan revealed a mass, which was later removed ...